0

Gastrointestinal Stromal Tumors Therapeutics Market by Route of Administration and Geography - Forecast and Analysis 2022-2026

  • Published: Sep 2022
  • Pages: 132
  • SKU: IRTNTR74250
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Safe and Secure SSL Encrypted

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

The gastrointestinal stromal tumors therapeutics market share is expected to increase by USD 1.08 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 5.97%.

This gastrointestinal stromal tumors therapeutics market research report provides valuable insights on the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers the gastrointestinal stromal tumors therapeutics market segmentation by route of administration (oral and parenteral) and geography (North America, Europe, Asia, and the Rest of the World (ROW)). The gastrointestinal stromal tumors therapeutics (GIST) market report also offers information on several market vendors, including Ascentage Pharma Group International, AB Science SA, Bayer AG, Blueprint Medicines Corp, Bristol Myers Squibb Co., Deciphera Pharmaceuticals Inc, Immunicum AB, NATCO Pharma Ltd., Novartis AG, Pfizer Inc., Sumitomo Pharma Oncology Inc., Sun Pharmaceutical Industries Ltd, Xencor Inc., and Arog Pharmaceuticals Inc among others.

What will the Gastrointestinal Stromal Tumors Therapeutics Market Size be During the Forecast Period?

Gastrointestinal Stromal Tumors Therapeutics Market Size

Download Report Sample to Unlock the Gastrointestinal Stromal Tumors Therapeutics Market Size for the Forecast Period and Other Important Statistics

 

Gastrointestinal Stromal Tumors Therapeutics Market: Key Drivers, Trends, and Challenges

Our researcher studied the historical data for years, with 2021 as the base year and 2022 as the estimated year, and produced drivers, trends, and challenges for the gastrointestinal stromal tumors therapeutics market. During the COVID-19 pandemic, the gastrointestinal stromal tumors therapeutics market demand has been impacted greatly. A holistic analysis of drivers will help exact demands and refine marketing strategies to gain a competitive advantage.

Key Gastrointestinal Stromal Tumors Therapeutics Market Driver

  • The growing geriatric population is one of the key factors driving the gastrointestinal stromal tumors therapeutics (GIST) market growth.
  • The risk of a person developing the disease increases with age. The advances in healthcare infrastructure and the increasing number of treatment options available for various indications, such as cancer, have increased the life expectancy of people globally. 
  • Factors such as the increasing awareness about various life-threatening indications have been contributing to higher life expectancy. 
  • Developing countries such as China, India, and Brazil are some of the fastest-growing countries in terms of the geriatric population. Factors such as the high population and the rapid advances in healthcare infrastructure in these countries are expected to further contribute to geriatric population growth. This, in turn, will drive market growth during the forecast period.

Key Gastrointestinal Stromal Tumors Therapeutics Market Trend

  • The advent of regenerative therapy is one of the key gastrointestinal stromal tumors therapeutics (GIST) market trends fueling the market growth.
  • A surgical procedure does not remove the tumor completely. As a result, therapeutics are often used as adjuvant therapy to treat the remaining portion of the tumor. Even after the complete removal of the tumor, the disease is known to recur in the future.
  • Research shows that various genes are associated with the progression of gastrointestinal stromal tumors. Some of the common genes that are known to cause cancer in the gastric tract are the KIT gene and the PDGFRA gene.
  • As a good proportion of the patient population becomes resistant to the treatment using GLEEVEC, SUTENT, and STIVARGA, the market witnesses a huge demand for personalized treatment options. 
  • The identification of gene mutation is leading to advances in therapeutics development, as various researchers are studying the use of gene therapy for the treatment of these tumors. Such factors will fuel market growth in the near future.

Key Gastrointestinal Stromal Tumors Therapeutics Market Challenge

  • High treatment costs are one of the factors limiting the gastrointestinal stromal tumors therapeutics (GIST)  market growth.
  • A major share of the global gastrointestinal stromal tumors therapeutics market is dominated by specialty drugs such as GLEEVEC, STIVARGA, and SUTENT, which contribute to approximately 70% of the market revenue. 
  • For instance, treatment using GLEEVEC costs $110,000-$120,000 per year or $9,000-$10,000 per month. Hence, many patients who do not have health insurance or access to patient assistance programs from vendors or governments do not adhere to treatment regimens, which reduces patient adherence and poses a challenge to market growth. 
  • Although the prices of generic drugs often decrease over time, with multiple generic versions entering the market, the global gastrointestinal stromal tumors therapeutics market will not likely be impacted by this threat until the late second half of the forecast period. 
  • The complex manufacturing process and high R&D costs of biologics often lead to vendors offering these drugs at a high price. The high treatment costs using therapeutics are expected to be one of the major challenges to the market's growth during the forecast period.

This gastrointestinal stromal tumors therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global gastrointestinal stromal tumors therapeutics market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the gastrointestinal stromal tumors therapeutics market during the forecast period.

Who are the Major Gastrointestinal Stromal Tumors Therapeutics Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

  • Ascentage Pharma Group International
  • AB Science SA
  • Bayer AG
  • Blueprint Medicines Corp
  • Bristol Myers Squibb Co.
  • Deciphera Pharmaceuticals Inc
  • Immunicum AB
  • NATCO Pharma Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sumitomo Pharma Oncology Inc.
  • Sun Pharmaceutical Industries Ltd
  • Xencor Inc.
  • Arog Pharmaceuticals Inc

 

This statistical study of the GIST therapeutics market encompasses successful business strategies deployed by the key vendors. The GIST therapeutics market is concentrated, and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Product Insights and News

  • oncology.sumitomo-pharma.com - The company offers gastrointestinal stromal tumors therapeutics such as antihypertensive therapy and Sutent.

To make the most of the opportunities and recover from the post-COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The vendor profiles are designed to help clients improve their market position and information on production and sustainability along with this the report provides a detailed analysis of several leading Companies.

Gastrointestinal Stromal Tumors Therapeutics Market Value Chain Analysis

Our In-house experts produce extensive information on the value chain and parent market of the gastrointestinal stromal tumors therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The Value Chain information provides an end-end understanding of product insight and profits and also optimization and evaluation of business strategies The players across the value chain include selective data and analysis from entire research findings as per the scope of the report.

Which are the Key Regions for the Gastrointestinal Stromal Tumors Therapeutics Market?

Gastrointestinal Stromal Tumors Therapeutics Market Share by Geography

For more insights on the market share of various regions Request PDF Sample now!

37% of the market’s growth will originate from North America during the forecast period. The US is the key market for the gastrointestinal stromal tumors therapeutics market in North America. Market growth in this region will be slower than the growth of the market in other regions.

The world's largest pharmaceutical market will facilitate the gastrointestinal stromal tumors therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID-19 Impact and Recovery Analysis

The outbreak of COVID-19 severely impacted the regional market in North America in 2020. However, with the initiation of vaccination drives and government initiatives in 2021, the market started recovering from the impact of the pandemic on growth. Owing to these factors, the regional market is expected to grow significantly during the forecast period.

What are the Revenue-generating Route of Administration Segments in the Gastrointestinal Stromal Tumors Therapeutics Market?

Gastrointestinal Stromal Tumors Therapeutics Market Share

To gain further insights on the market contribution of various segments Request a PDF Sample

The gastrointestinal stromal tumors therapeutics market share growth by the oral segment will be significant during the forecast period. The oral segment is expected to witness a number of generic drugs entering the market. Despite the expected volume growth, the entry of generics is expected to cause value erosion, owing to their low prices. This is expected to result in the oral segment losing some of its market share to the parenteral segment. However, the demand for these drugs is expected to remain higher than that for parenteral drugs during the forecast period, which results in a partial offset of the damage caused.

This report provides an accurate prediction of the contribution of all the segments to the growth of the GIST therapeutics market size and actionable market insights on the post-COVID-19 impact on each segment.

 

Gastrointestinal Stromal Tumors Therapeutics Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 5.97%

Market growth 2022-2026

$1.08 billion

Market structure

Concentrated

YoY growth (%)

5.43

Regional analysis

North America, Europe, Asia, and the Rest of the World (ROW)

Performing market contribution

North America at 37%

Key consumer countries

US, UK, France, China, and Japan

Competitive landscape

Leading companies, Competitive Strategies, Consumer engagement scope

Key companies profiled

Ascentage Pharma Group International, AB Science SA, Bayer AG, Blueprint Medicines Corp, Bristol Myers Squibb Co., Deciphera Pharmaceuticals Inc, Immunicum AB, NATCO Pharma Ltd., Novartis AG, Pfizer Inc., Sumitomo Pharma Oncology Inc., Sun Pharmaceutical Industries Ltd, Xencor Inc., and Arog Pharmaceuticals Inc

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Gastrointestinal Stromal Tumors Therapeutics Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive gastrointestinal stromal tumors therapeutics market growth during the next five years
  • Precise estimation of the gastrointestinal stromal tumors therapeutics market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the gastrointestinal stromal tumors therapeutics industry across North America, Europe, Asia, and the Rest of the World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of gastrointestinal stromal tumors therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
    • 3.4 Market outlook: Forecast for 2021-2026
      • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
      • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

    4 Five Forces Analysis

    • 4.1 Five forces summary
      • Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
    • 4.2 Bargaining power of buyers
      • Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
    • 4.3 Bargaining power of suppliers
      • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
    • 4.4 Threat of new entrants
      • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
    • 4.5 Threat of substitutes
      • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
    • 4.6 Threat of rivalry
      • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
    • 4.7 Market condition
      • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

    5 Market Segmentation by Route of Administration

    • 5.1 Market segments
      • Exhibit 24: Chart on Route of Administration - Market share 2021-2026 (%)
      • Exhibit 25: Data Table on Route of Administration - Market share 2021-2026 (%)
    • 5.2 Comparison by Route of Administration
      • Exhibit 26: Chart on Comparison by Route of Administration
      • Exhibit 27: Data Table on Comparison by Route of Administration
    • 5.3 Oral - Market size and forecast 2021-2026
      • Exhibit 28: Chart on Oral - Market size and forecast 2021-2026 ($ million)
      • Exhibit 29: Data Table on Oral - Market size and forecast 2021-2026 ($ million)
      • Exhibit 30: Chart on Oral - Year-over-year growth 2021-2026 (%)
      • Exhibit 31: Data Table on Oral - Year-over-year growth 2021-2026 (%)
    • 5.4 Parenteral - Market size and forecast 2021-2026
      • Exhibit 32: Chart on Parenteral - Market size and forecast 2021-2026 ($ million)
      • Exhibit 33: Data Table on Parenteral - Market size and forecast 2021-2026 ($ million)
      • Exhibit 34: Chart on Parenteral - Year-over-year growth 2021-2026 (%)
      • Exhibit 35: Data Table on Parenteral - Year-over-year growth 2021-2026 (%)
    • 5.5 Market opportunity by Route of Administration
      • Exhibit 36: Market opportunity by Route of Administration ($ million)

    6 Customer Landscape

    • 6.1 Customer landscape overview
      • Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    7 Geographic Landscape

    • 7.1 Geographic segmentation
      • Exhibit 38: Chart on Market share by geography 2021-2026 (%)
      • Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
    • 7.2 Geographic comparison
      • Exhibit 40: Chart on Geographic comparison
      • Exhibit 41: Data Table on Geographic comparison
    • 7.3 North America - Market size and forecast 2021-2026
      • Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
      • Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
    • 7.4 Europe - Market size and forecast 2021-2026
      • Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
      • Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
    • 7.5 Asia - Market size and forecast 2021-2026
      • Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
      • Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
    • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
      • Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
      • Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
    • 7.7 US - Market size and forecast 2021-2026
      • Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
      • Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
    • 7.8 UK - Market size and forecast 2021-2026
      • Exhibit 62: Chart on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 63: Data Table on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 64: Chart on UK - Year-over-year growth 2021-2026 (%)
      • Exhibit 65: Data Table on UK - Year-over-year growth 2021-2026 (%)
    • 7.9 China - Market size and forecast 2021-2026
      • Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%)
      • Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%)
    • 7.10 France - Market size and forecast 2021-2026
      • Exhibit 70: Chart on France - Market size and forecast 2021-2026 ($ million)
      • Exhibit 71: Data Table on France - Market size and forecast 2021-2026 ($ million)
      • Exhibit 72: Chart on France - Year-over-year growth 2021-2026 (%)
      • Exhibit 73: Data Table on France - Year-over-year growth 2021-2026 (%)
    • 7.11 Japan - Market size and forecast 2021-2026
      • Exhibit 74: Chart on Japan - Market size and forecast 2021-2026 ($ million)
      • Exhibit 75: Data Table on Japan - Market size and forecast 2021-2026 ($ million)
      • Exhibit 76: Chart on Japan - Year-over-year growth 2021-2026 (%)
      • Exhibit 77: Data Table on Japan - Year-over-year growth 2021-2026 (%)
    • 7.12 Market opportunity by geography
      • Exhibit 78: Market opportunity by geography ($ million)

    8 Drivers, Challenges, and Trends

    • 8.1 Market drivers
      • 8.2 Market challenges
        • 8.3 Impact of drivers and challenges
          • Exhibit 79: Impact of drivers and challenges in 2021 and 2026
        • 8.4 Market trends

          9 Vendor Landscape

          • 9.1 Overview
            • 9.2 Vendor landscape
              • Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
            • 9.3 Landscape disruption
              • Exhibit 81: Overview on factors of disruption
            • 9.4 Industry risks
              • Exhibit 82: Impact of key risks on business

            10 Vendor Analysis

            • 10.1 Vendors covered
              • Exhibit 83: Vendors covered
            • 10.2 Market positioning of vendors
              • Exhibit 84: Matrix on vendor position and classification
            • 10.3 Ascentage Pharma Group International
              • Exhibit 85: Ascentage Pharma Group International - Overview
              • Exhibit 86: Ascentage Pharma Group International - Business segments
              • Exhibit 87: Ascentage Pharma Group International - Key offerings
              • Exhibit 88: Ascentage Pharma Group International - Segment focus
            • 10.4 Bayer AG
              • Exhibit 89: Bayer AG - Overview
              • Exhibit 90: Bayer AG - Business segments
              • Exhibit 91: Bayer AG - Key offerings
              • Exhibit 92: Bayer AG - Segment focus
            • 10.5 Blueprint Medicines Corp
              • Exhibit 93: Blueprint Medicines Corp - Overview
              • Exhibit 94: Blueprint Medicines Corp - Product / Service
              • Exhibit 95: Blueprint Medicines Corp - Key news
              • Exhibit 96: Blueprint Medicines Corp - Key offerings
            • 10.6 Bristol Myers Squibb Co.
              • Exhibit 97: Bristol Myers Squibb Co. - Overview
              • Exhibit 98: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 99: Bristol Myers Squibb Co. - Key offerings
            • 10.7 Deciphera Pharmaceuticals Inc
              • Exhibit 100: Deciphera Pharmaceuticals Inc - Overview
              • Exhibit 101: Deciphera Pharmaceuticals Inc - Business segments
              • Exhibit 102: Deciphera Pharmaceuticals Inc - Key news
              • Exhibit 103: Deciphera Pharmaceuticals Inc - Key offerings
              • Exhibit 104: Deciphera Pharmaceuticals Inc - Segment focus
            • 10.8 Immunicum AB
              • Exhibit 105: Immunicum AB - Overview
              • Exhibit 106: Immunicum AB - Business segments
              • Exhibit 107: Immunicum AB - Key offerings
              • Exhibit 108: Immunicum AB - Segment focus
            • 10.9 Novartis AG
              • Exhibit 109: Novartis AG - Overview
              • Exhibit 110: Novartis AG - Business segments
              • Exhibit 111: Novartis AG - Key offerings
              • Exhibit 112: Novartis AG - Segment focus
            • 10.10 Pfizer Inc.
              • Exhibit 113: Pfizer Inc. - Overview
              • Exhibit 114: Pfizer Inc. - Product / Service
              • Exhibit 115: Pfizer Inc. - Key news
              • Exhibit 116: Pfizer Inc. - Key offerings
            • 10.11 Sun Pharmaceutical Industries Ltd
              • Exhibit 117: Sun Pharmaceutical Industries Ltd - Overview
              • Exhibit 118: Sun Pharmaceutical Industries Ltd - Product / Service
              • Exhibit 119: Sun Pharmaceutical Industries Ltd - Key offerings
            • 10.12 Xencor Inc.
              • Exhibit 120: Xencor Inc. - Overview
              • Exhibit 121: Xencor Inc. - Product / Service
              • Exhibit 122: Xencor Inc. - Key news
              • Exhibit 123: Xencor Inc. - Key offerings

            11 Appendix

            • 11.1 Scope of the report
              • 11.2 Inclusions and exclusions checklist
                • Exhibit 124: Inclusions checklist
                • Exhibit 125: Exclusions checklist
              • 11.3 Currency conversion rates for US$
                • Exhibit 126: Currency conversion rates for US$
              • 11.4 Research methodology
                • Exhibit 127: Research methodology
                • Exhibit 128: Validation techniques employed for market sizing
                • Exhibit 129: Information sources
              • 11.5 List of abbreviations
                • Exhibit 130: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              TechnavioINFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases
              Technavio

              TechnavioDATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts
              Technavio

              TechnavioREPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape
              Interested in this report?
              Get your sample now!
              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?
              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis

              Certified ISO 9001 : 2015

              We are ISO recognized

              We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

              We are GDPR and CCPA compliant

              We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

              Safe and Secure SSL Encrypted
              Technavio

              info
              close
              • Single:

                One user only.
                Quick & easy download option

              • Enterprise:

                Unlimited user access (Within your organization)
                Complimentary Customization Included

              2500 USD

              Technavio Get the report (PDF) sent to your email within minutes.

              Subscribe & Save

              Get lifetime access to our
              Technavio Insights

              Customized Report as per your Business Needs

              • Our analysts will work directly with you and understand your needs
              • Get data on specified regions or segments, competitor and Vendors
              • Data will be formatted and presented as per your requirements
              • We offer $1000 worth of FREE customization at the time of purchase

              Let us help you make report more suited to your requirements.

              • Get a competitive breakdown as per your niche industry
              • Customize the data with various metrics that meet your business prerequisite
              • Understand Revenue Sources, Customers and many more
              • Details on Market Share
              • These customizations are done in a short amount of time by our analysts and industry experts
              Technavio
              Enquire Before Buying
              17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>